Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.276
Neutral
RSI(14)
52.960
Neutral
STOCH(KDJ)(9,3,3)
55.360
Neutral
ATR(14)
0.476
Low Volatility
CCI(14)
68.110
Neutral
Williams %R
31.527
Buy
TRIX(12,20)
-0.060
Sell
StochRSI(14)
83.392
Buy
Search
Pfizer Inc
PFEAdd to Watchlist
24.995USD
+0.175+0.71%
Close 07-23 16:00（ET）Quotes delayed by 15 min
142.45BMarket Cap
18.98P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.71%
5 Days
-0.58%
1 Month
+1.11%
6 Months
-2.55%
Year to Date
+0.38%
1 Year
-1.44%
Key Figures
24.890Open
25.100High
30.88MVolume
18.98P/E TTM
8.78P/E Dynamic
1.720Dividend TTM
0.54%Turnover Ratio
24.820Prev. Close
24.750Low
455.39MTurnover
17.74P/E Static
1.58P/B
6.88%Div Yield TTM
3.62%ROA
28.74552wk High
0.79Volume Ratio
8.03BNet Profit
5.70BShares
1.3167EPS TTM
0.30Beta
8.29%ROE
23.06052wk Low
1.41%Amplitude
68.24%Gross Margin
142.45BMarket Cap
2.41Reward/Risk
1.35%Risk Rate
TradingKey Stock Score of Pfizer Inc
Currency: USD Updated: 2026-07-23Key Insights
Pfizer Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 28.58.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pfizer Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
48°C
Very Low
Very High
Negative
Pfizer Inc Highlights
StrengthsRisks
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 62.58B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.
Overvalued
The company’s latest PE is 18.99, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.98B shares, increasing 0.73% quarter-over-quarter.
Held by Irving Kahn
Star Investor Irving Kahn holds 510.87K shares of this stock.
Analyst Rating
Based on
32
analysts
Hold
Current Rating
28.579
Target Price
+14.59%
Upside Space
Pfizer Inc News
China Adds Eli Lilly and Pfizer to Its First Private Insurance List — Is This a Buying Opportunity for Biotech Investors?
TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).
TradingKeyMon, Dec 8
The Strategic Repositioning Driving Pfizer's Growth Story
TradingKey - Pfizer’s non-COVID portfolio grew 12% in 2024, led by a 65% surge in Vyndaqel sales and 26% oncology revenue growth.
TradingKeyApr 8, 2025
Earnings Forecast
Analyst Rating
Based on
32
analysts
Hold
Current Rating
28.579
Target Price
+14.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Pfizer Inc
PFE
32
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Merck & Co Inc
MRK
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
24.914
Buy
MA10
24.743
Buy
MA20
24.406
Buy
MA50
25.172
Sell
MA100
26.096
Sell
MA200
25.849
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pfizer Inc Info
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Ticker SymbolPFE
CompanyPfizer Inc
CEOBourla (Albert)
Websitehttps://www.pfizer.com/
Shareholders
Related Instruments
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+1.49%
+0.38%
0.00%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+0.11%
+8.61%
-0.21%
+2.45%Popular Instruments
FAQs
What is the current price of Pfizer Inc (PFE)?
The current price of Pfizer Inc (PFE) is 25.00.
What is the symbol of Pfizer Inc?
The ticker symbol of Pfizer Inc is PFE.
What is the 52-week high of Pfizer Inc?
The 52-week high of Pfizer Inc is 28.75.
What is the 52-week low of Pfizer Inc?
The 52-week low of Pfizer Inc is 23.06.
What is the market capitalization of Pfizer Inc?
The market capitalization of Pfizer Inc is 142.45B.
Is Pfizer Inc (PFE) currently rated as Buy, Hold, or Sell?
According to analysts, Pfizer Inc (PFE) has an overall rating of signal_hold, with a price target of 28.58.
What is the Earnings Per Share (EPS TTM) of Pfizer Inc (PFE)?
The Earnings Per Share (EPS TTM) of Pfizer Inc (PFE) is 1.37.